Tiziano Barbui
Tiziano Barbui
Fondazione per la Ricerca Ospedale Maggiore di Bergamo
Verified email at asst-pg23.it
TitleCited byYear
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
M Galli, T Barbui, P Comfurius, C Maassen, HC Hemker, RFA Zwaal, ...
The Lancet 335 (8705), 1544-1547, 1990
16061990
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
C Harrison, JJ Kiladjian, HK Al-Ali, H Gisslinger, R Waltzman, ...
New England Journal of Medicine 366 (9), 787-798, 2012
12412012
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis …
A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ...
Blood 110 (4), 1092-1097, 2007
9882007
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
M Galli, D Luciani, G Bertolini, T Barbui
Blood 101 (5), 1827-1832, 2003
9612003
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ...
New England Journal of Medicine 350 (2), 114-124, 2004
9092004
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
S Cortelazzo, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, ...
New England Journal of Medicine 332 (17), 1132-1137, 1995
8861995
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
EM Bevers, M Galli, T Barbui, P Comfurius, RFA Zwaal
Thrombosis and haemostasis 66 (06), 629-632, 1991
7041991
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ...
Journal of Clinical Oncology 29 (6), 761, 2011
6832011
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA …
MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ...
Blood 96 (4), 1247-1253, 2000
6072000
Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
F Mandelli, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, ...
Blood 90 (3), 1014-1021, 1997
5921997
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli, G Finazzi, R Landolfi, J Kutti, H Gisslinger, C Patrono, ...
Journal of Clinical Oncology 23 (10), 2224-2232, 2005
5672005
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
P Rebulla, G Finazzi, F Marangoni, G Avvisati, L Gugliotta, G Tognoni, ...
New England Journal of Medicine 337 (26), 1870-1875, 1997
5571997
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
Italian Cooperative Study Group on Chronic Myeloid Leukemia
New England Journal of Medicine 330 (12), 820-825, 1994
5391994
Cardiovascular events and intensity of treatment in polycythemia vera
R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ...
New England Journal of Medicine 368 (1), 22-33, 2013
5302013
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid …
G Finazzi, R Marchioli, V Brancaccio, P Schinco, F Wisloff, J Musial, ...
Journal of Thrombosis and Haemostasis 3 (5), 848-853, 2005
5302005
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
S Cortelazzo, P Viero, G Finazzi, A D'Emilio, F Rodeghiero, T Barbui
Journal of Clinical Oncology 8 (3), 556-562, 1990
5021990
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry
G Finazzi, V Brancaccio, M Moia, N Ciavarella, MG Mazzucconi, ...
The American journal of medicine 100 (5), 530-536, 1996
4851996
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ...
Blood 98 (12), 3383-3389, 2001
4742001
Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia
AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ...
Blood 110 (3), 840-846, 2007
4732007
Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome
M Galli, D Luciani, G Bertolini, T Barbui
Blood 102 (8), 2717-2723, 2003
4432003
The system can't perform the operation now. Try again later.
Articles 1–20